Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Newegg Commerce Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Newegg Commerce Inc trades at $14.1 (market cap $295.52M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 27.2× Newegg Commerce Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| BIO | NEGG | |
|---|---|---|
Market Cap | $8.04B | $295.52M |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $128.09 |
52-Week Low | $241.71 | $13.87 |
Enterprise Value | $7.85B | $294.32M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
NEGG trades at $13.87, down 1.98% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $4.88 million for 2025, though revenue improved to $1.44 billion. Recent news highlights AI shopping initiatives and the FantasTech sale, indicating ongoing business development efforts. Cash flow from operations remains negative at -$26.97 million, but financing activities provided a net cash inflow of $8.91 million.
The outlook is mixed; a single analyst rates NEGG a buy, and profitability may recover by 2026. However, persistent operating losses, weak cash generation, and high debt-to-asset ratios pose significant risks. Investors should weigh potential e-commerce growth against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
